Brachytherapy
Volume 6, Issue 1 , Pages 16-25, January 2007

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

  • Rodney J. Ellis

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH
    • Department of Radiology, Northeastern Ohio Universities College of Medicine, Rootstown, OH
    • Division of Urology, MetroHealth Medical Center, University Hospitals of Cleveland, Cleveland, OH
    • Corresponding Author InformationCorresponding author. Stark Radiation Oncology, 2600 Sixth Street, SW, PO Box 80468, Canton, OH 44710, USA. Tel.: +1-330-363-6201; fax: +1-330-454-9397.
    • ,
  • Hang Zhou

      Affiliations

    • Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH
    • Department of Epidemiology and Biostatistics, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Edward Y. Kim

      Affiliations

    • Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Pingfu Fu

      Affiliations

    • Department of Epidemiology and Biostatistics, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Deborah A. Kaminsky

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • ,
  • Bruce Sodee

      Affiliations

    • Department of Radiology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Valdir Colussi

      Affiliations

    • Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Waseet Z. Vance

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • ,
  • John P. Spirnak

      Affiliations

    • Division of Urology, MetroHealth Medical Center, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Carolyn Kim

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • ,
  • Martin I. Resnick

      Affiliations

    • Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH

Received 1 August 2006; received in revised form 1 November 2006; accepted 3 November 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This article includes uses of a US Food and Drug Admistration approved agent (ProstaScint) outside its current labeled indications. The agent's package insert should be consulted for complete prescribing information.Financial Disclosure: Dr. Ellis has an unrestricted research grant and speakers bureau funding from the Cytogen Corporation, Princeton, NJ.

PII: S1538-4721(06)00299-6

doi:10.1016/j.brachy.2006.11.002

Brachytherapy
Volume 6, Issue 1 , Pages 16-25, January 2007

Article Tools

* Image Usage & Resolution